宏基因组二代测序早期检测脓毒症病原体的临床应用进展  

Advances in clinical application of metagenomic next-generation sequencing for early detection of pathogens in sepsis

作　　者：王黎(综述) 丁艳辉[2] 曹子鋆 薛建江 王晓亮(审校) WANG Li;DING Yanhui;CAO Zijun;XUE Jianjiang;WANG Xiaoliang(Medical Science Research Center/Department of Laboratory Medicine,University Town Hospital of Chongqing Medical University,Chongqing 401331,China;Department of Laboratory Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属大学城医院医学科学研究中心/检验科,重庆401331 [2]重庆医科大学附属第一医院检验科,重庆400016

出　　处：《现代医药卫生》2024年第18期3197-3201,3206,共6页Journal of Modern Medicine & Health

基　　金：重庆市自然科学基金项目(cstc2019jcyj-msxmX0294);重庆市教委科学技术研究项目(KJQN202000444)。

摘　　要：脓毒症患者存活率低、死亡率高、预后差,早期识别其病原体尤为关键。宏基因组二代测序(mNGS)能实现无偏倚检测临床样本中的所有微生物,对早期发现脓毒症病原微生物较传统培养技术等更灵敏、准确、高效。随着二代测序技术的不断发展,mNGS在诊断脓毒症方面的临床应用价值将进一步提高,该文就mNGS在脓毒症早期诊断中的优势、临床应用及进展、挑战与展望进行综述。Sepsis patients have low survival rates,high mortality rates,and poor prognosis,making early identification of pathogens particularly crucial.Metagenomic next-generation sequencing(mNGS)enables unbiased detection of all microorganisms in clinical samples,providing greater sensitivity,accuracy,and efficiency in early detection of sepsis pathogenic microorganism compared to traditional culture techniques.With the continuous development of next-generation sequencing technology,the clinical application value of mNGS in sepsis diagnosis will further improve.This article reviews the advantages,clinical applications,progress,challenges,and prospects of mNGS in the early diagnosis of sepsis.

关 键 词：宏基因组二代测序 脓毒症 病原微生物 早期检测 综述 

分 类 号：R446.5[医药卫生—诊断学]